50 Participants Needed

BPM31510 + Vitamin K1 for Glioblastoma

Recruiting at 10 trial locations
EG
ND
BB
VM
AL
SN
Overseen BySeema Nagpal, MD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Will I have to stop taking my current medications?

You may need to stop taking certain medications to participate in this trial. Specifically, you cannot take therapeutic doses of anticoagulants (blood thinners), digitalis alkaloids (heart medications), antiangiogenic drugs (cancer treatments), or theophylline (a medication for breathing problems).

What data supports the effectiveness of the drug BPM31510 + Vitamin K1 for treating glioblastoma?

Research shows that BPM31510, which delivers high levels of ubidecarenone (a form of CoQ10), can selectively target and kill glioblastoma cells by exploiting their vulnerability to oxidative stress. In animal models, this approach led to a significant increase in long-term survival rates, suggesting its potential as an effective treatment for this aggressive brain cancer.12345

Is BPM31510 (ubidecarenone) safe for human use?

Ubidecarenone (CoQ10) has been used safely as a dietary supplement and in complementary therapies for heart failure for over two decades, with no reported genotoxic (DNA-damaging) effects in studies. Additionally, CoQ10 formulations have shown no obvious toxicity in lung cell studies, suggesting it is generally safe for human use.16789

What makes the drug BPM31510 + Vitamin K1 unique for treating glioblastoma?

BPM31510 delivers high levels of ubidecarenone (a form of Coenzyme Q10) directly to cancer cells, exploiting their vulnerability to oxidative stress, which can selectively kill tumor cells without harming normal cells. This approach is novel because it targets the cancer cells' unique metabolic reprogramming, unlike most treatments that do not differentiate between cancerous and non-cancerous cells.1241011

What is the purpose of this trial?

This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess the effects of adding BPM31510 onto a conventional treatment framework of RT and concurrent TMZ chemotherapy for subjects with newly diagnosed glioblastoma.

Eligibility Criteria

This trial is for adults over 18 with newly diagnosed glioblastoma who haven't had prior treatments like radiation or chemotherapy. They should be able to understand the study and consent, have a life expectancy of at least 3 months, and a Karnofsky score of 60 or more. Participants must not be pregnant, avoid pregnancy during the trial, and be two weeks post-surgery.

Inclusion Criteria

It has been at least 14 days since my surgery.
Life expectancy ≥3 months
I have been newly diagnosed with a glioblastoma.
See 5 more

Exclusion Criteria

I have taken drugs like Avastin recently or plan to in the next 2 weeks.
I am currently taking heart medication such as Digoxin.
You are allergic to CoQ10.
See 12 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dose-confirmation

Establish safety of BPM31510 in combination with RT and TMZ using a 3+3 dose design

8 weeks
Weekly visits for infusion

Treatment

Participants receive BPM31510 infusion and concurrent RT and TMZ chemotherapy

8 weeks
Weekly visits for infusion and daily RT and TMZ

Follow-up

Participants are monitored for safety and effectiveness after treatment

5 years
Every 8 weeks for the first year, then every 12 weeks

Treatment Details

Interventions

  • BPM31510
Trial Overview The study tests BPM31510 combined with Vitamin K1 alongside standard treatment (radiation therapy and TMZ chemotherapy) for glioblastoma. It's an open-label Phase 2 trial where all participants receive this combination to see how effective it is compared to traditional methods alone.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: BPM31510, Vitamin K1, RT and TMZExperimental Treatment4 Interventions
Subjects will receive a BPM31510 96hr infusion once weekly for 8 wk. Prophylactic Vitamin K1 at a recommended dose of 10 mg will be given intramuscular (IM) to all subjects prior to the beginning of each week of therapy. After 2 wk of treatment with BPM31510, subjects will start concurrent standard RT and TMZ 75 mg/m2 once daily (qd) × 42 days. Subjects will receive the standard TMZ treatment for additional 6 cycles post BPM31510 treatment.

Find a Clinic Near You

Who Is Running the Clinical Trial?

BPGbio

Lead Sponsor

Trials
13
Recruited
2,200+

Berg, LLC

Lead Sponsor

Trials
13
Recruited
2,200+

BPGbio

Collaborator

Trials
1
Recruited
50+

Findings from Research

Ubidecarenone, delivered through BPM31510, shows a significant therapeutic potential against glioblastoma, as it selectively targets cancer cells with elevated oxidative stress, leading to increased sensitivity compared to non-cancer cells.
In vivo studies demonstrated that treatment with ubidecarenone resulted in over 25% long-term survival in a rodent glioma model, indicating its effectiveness in enhancing survival in aggressive cancer types.
High levels of ubidecarenone (oxidized CoQ10) delivered using a drug-lipid conjugate nanodispersion (BPM31510) differentially affect redox status and growth in malignant glioma versus non-tumor cells.Sun, J., Patel, CB., Jang, T., et al.[2021]
Coenzyme Q10 (CoQ10) significantly reduced tumor volume in glioblastoma multiforme (GBM) models by decreasing hypoxia and vascularization, while also limiting inflammatory cell infiltration.
CoQ10's effects on GBM were linked to the downregulation of key proteins like HIF-1α and NF-kB, leading to changes in tumor cell behavior, including reduced migration and invasion, suggesting it could be a valuable addition to current GBM therapies.
CoQ10 reduces glioblastoma growth and infiltration through proteome remodeling and inhibition of angiogenesis and inflammation.Frontiñán-Rubio, J., Llanos-González, E., García-Carpintero, S., et al.[2023]
In a study involving 483 pregnancies and 615 blood samples, low maternal Coenzyme Q10 (CoQ10) levels were associated with spontaneous abortions and threatened late abortions, suggesting that CoQ10 could serve as a marker for pathological uterine activity.
Fetal CoQ10 levels were significantly elevated in cases of non-immune fetal hydrops, indicating that increased CoQ10 may be linked to fetal distress or hypoxia.
[The antioxidants (coenzyme Q10) in materno-fetal physiopathology].Noia, G., Romano, D., De Santis, M., et al.[2014]

References

High levels of ubidecarenone (oxidized CoQ10) delivered using a drug-lipid conjugate nanodispersion (BPM31510) differentially affect redox status and growth in malignant glioma versus non-tumor cells. [2021]
CoQ10 reduces glioblastoma growth and infiltration through proteome remodeling and inhibition of angiogenesis and inflammation. [2023]
[The antioxidants (coenzyme Q10) in materno-fetal physiopathology]. [2014]
4.Russia (Federation)pubmed.ncbi.nlm.nih.gov
GLIOMA CELL PROLIFERATION MEDIATED BY COENZYME Q10 AT SERUM DEPRIVATION IN VITRO. [2018]
Improved photostability and cytotoxic effect of coenzyme Q10 by its association with vitamin E acetate in polymeric nanocapsules. [2018]
Nebulized coenzyme Q10 nanosuspensions: A versatile approach for pulmonary antioxidant therapy. [2018]
Genotoxicity studies of ubidecarenone (coenzyme Q10) manufactured by bacteria fermentation. [2019]
Evaluation of the mutagenic potential of ubidecarenone using three short-term assays. [2014]
Formulation and evaluation of ubidecarenone transdermal delivery systems. [2014]
Comparison of vitamins K1, K2 and K3 effects on growth of rat glioma and human glioblastoma multiforme cells in vitro. [2013]
Biomarkers Regulated by Lipid-Soluble Vitamins in Glioblastoma. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security